Application of the REVEAL risk score calculator 2.0 in the CHEST study

Raymond L. Benza; Harrison W. Farber; Adaani E. Frost; Hossein Ardeschir Ghofrani; Paul A. Corris; Marc Lambelet; Sylvia Nikkho; Christian Meier; Marius M. Hoeper

doi:10.1016/j.rmed.2022.106783

Application of the REVEAL risk score calculator 2.0 in the CHEST study

Raymond L. Benza, Harrison W. Farber, Adaani E. Frost, Hossein Ardeschir Ghofrani, Paul A. Corris, Marc Lambelet, Sylvia Nikkho, Christian Meier, Marius M. Hoeper

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS. Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS). Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2. Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.

Original language	English (US)
Article number	106783
Pages (from-to)	106783
Journal	Respiratory Medicine
Volume	195
DOIs	https://doi.org/10.1016/j.rmed.2022.106783
State	Published - Apr 1 2022

Keywords

Chronic thromboembolic pulmonary hypertension
CTEPH
Pulmonary hypertension
Riociguat
Risk assessment
Risk Assessment
Humans
Pulmonary Embolism/complications
Risk Factors
Hypertension, Pulmonary
Treatment Outcome
Pulmonary Arterial Hypertension
Chronic Disease

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.rmed.2022.106783

Cite this

@article{d25acae7df854ae7a65263d811c0cab2,

title = "Application of the REVEAL risk score calculator 2.0 in the CHEST study",

abstract = "Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS. Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS). Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2. Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.",

keywords = "Chronic thromboembolic pulmonary hypertension, CTEPH, Pulmonary hypertension, Riociguat, Risk assessment, Risk Assessment, Humans, Pulmonary Embolism/complications, Risk Factors, Hypertension, Pulmonary, Treatment Outcome, Pulmonary Arterial Hypertension, Chronic Disease",

author = "Benza, {Raymond L.} and Farber, {Harrison W.} and Frost, {Adaani E.} and Ghofrani, {Hossein Ardeschir} and Corris, {Paul A.} and Marc Lambelet and Sylvia Nikkho and Christian Meier and Hoeper, {Marius M.}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.rmed.2022.106783",

language = "English (US)",

volume = "195",

pages = "106783",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Application of the REVEAL risk score calculator 2.0 in the CHEST study

AU - Benza, Raymond L.

AU - Farber, Harrison W.

AU - Frost, Adaani E.

AU - Ghofrani, Hossein Ardeschir

AU - Corris, Paul A.

AU - Lambelet, Marc

AU - Nikkho, Sylvia

AU - Meier, Christian

AU - Hoeper, Marius M.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS. Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS). Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2. Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.

AB - Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for risk assessment in patients with pulmonary arterial hypertension, has previously predicted outcomes in CTEPH. RRS 2.0 was developed to refine the RRS. Methods: This post hoc analysis of the CHEST study (n = 237), which assessed riociguat in patients with inoperable and persistent/recurrent CTEPH, evaluated RRS 2.0 and its relationship with survival and clinical worsening-free survival (CWFS). Results: At CHEST-1 Week 16, RRS 2.0 significantly improved and more patients moved into the low-risk stratum with riociguat versus placebo; these improvements were maintained at CHEST-2 Week 12. RRS 2.0 at CHEST-1 baseline and Week 16, and change in RRS 2.0 from CHEST-1 baseline to Week 16 were significant predictors of survival and CWFS in CHEST-2. Conclusions: Our data suggest that RRS 2.0 may have utility in predicting outcomes and monitoring treatment response in patients with inoperable or persistent/recurrent CTEPH.

KW - Chronic thromboembolic pulmonary hypertension

KW - CTEPH

KW - Pulmonary hypertension

KW - Riociguat

KW - Risk assessment

KW - Risk Assessment

KW - Humans

KW - Pulmonary Embolism/complications

KW - Risk Factors

KW - Hypertension, Pulmonary

KW - Treatment Outcome

KW - Pulmonary Arterial Hypertension

KW - Chronic Disease

UR - http://www.scopus.com/inward/record.url?scp=85125751999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125751999&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2022.106783

DO - 10.1016/j.rmed.2022.106783

M3 - Article

C2 - 35256218

AN - SCOPUS:85125751999

SN - 0954-6111

VL - 195

SP - 106783

JO - Respiratory Medicine

JF - Respiratory Medicine

M1 - 106783

ER -

Application of the REVEAL risk score calculator 2.0 in the CHEST study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this